Citi upgraded Dr Reddy's Laboratories, raising target price on positive catalyst call citing semaglutide resumption

Tue 29 Sep 2026

Stock move

about 1 percent

Heard on Live TV News Channel between 10:53:55 - 10:55:10 IST.

• Citi issued a 90-day positive catalyst call on Dr Reddy's and raised the target price.
• Stock closed up about a percent and saw a slight further uptick.
• Analysts said tough period for DRL with multiple challenges, but incremental revenue expected from resumption of semaglutide.
• Stock remains in focus and on radar due to this development.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.